Hey, wait up Am­gen and Mi­rati, Boehringer In­gel­heim is join­ing the KRAS crowd as ear­ly suc­cess in­spires ri­vals

It doesn’t take long for hot new can­cer tar­gets to at­tract a bustling field of ri­vals. Take KRAS, for ex­am­ple.

To­day you can add Boehringer In­gel­heim to the group with clin­i­cal-stage KRAS as­sets to boast about. In­ves­ti­ga­tors pre­sent­ed their pre­clin­i­cal case for the oral KRAS in­hibitor BI 1701963 in Boston to­day, and un­veiled plans to go af­ter a full slate of KRAS mu­ta­tions in a move aimed be­yond just G12C, where Am­gen and Mi­rati are now vy­ing for the lead with promis­ing, but very ear­ly, lung can­cer da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER